Literature DB >> 11555573

PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.

T Minaguchi1, H Yoshikawa, K Oda, T Ishino, T Yasugi, T Onda, S Nakagawa, K Matsumoto, K Kawana, Y Taketani.   

Abstract

Although the prognostic impact of PTEN mutation in endometrial carcinoma is beginning to be analyzed, the prognostic significance of mutated PTEN exons has not ever been described. Sixty-seven endometrial carcinomas were analyzed for PTEN mutations using single-strand conformation polymorphism analysis and DNA sequencing. First, survival rates were compared according to PTEN status and mutated PTEN exons. Subsequently, univariate and multivariate analyses of various favorable prognostic factors for survival were conducted. The associations between PTEN mutation and clinicopathological features were also statistically evaluated. PTEN mutations were detected in 37 of 67 (55%) specimens. Among 47 mutations, frameshifts (57%) and mutations in exon 8 (38%) were most frequent. In univariate analysis, a factor of PTEN mutation only outside exons 5-7 was associated with significantly better survival (P = 0.02), although mutation in any exon of PTEN was not (P = 0.33). Subsequent multivariate analysis revealed that factors of mutation only outside exons 5-7 of PTEN, stage I/II, and G1 were significant and independent prognostic indicators for favorable survival (P = 0.004, 0.004, and 0.0006, respectively). In the subset of advanced-stage disease, mutation only outside exons 5-7 was associated with a trend toward better survival (P = 0.13). No significant correlation was observed between PTEN mutation and estrogen-related clinicopathological features. In conclusion, we find that PTEN mutation located only outside exons 5-7 is a significant and independent positive prognostic indicator for survival. The current observation has prognostic and therapeutic implications for the management of patients with endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555573

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.

Authors:  Li-E Wang; Hongxia Ma; Katherine S Hale; Ming Yin; Larissa A Meyer; Hongliang Liu; Jie Li; Karen H Lu; Bryan T Hennessy; Xuesong Li; Margaret R Spitz; Qingyi Wei; Gordon B Mills
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-07       Impact factor: 4.553

Review 2.  Molecular staging of gynecological cancer: What is the future?

Authors:  Pratibha S Binder; Jaime Prat; David G Mutch
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2015-03-04       Impact factor: 5.237

3.  PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.

Authors:  Shannon N Westin; Zhenlin Ju; Russell R Broaddus; Camilla Krakstad; Jane Li; Navdeep Pal; Karen H Lu; Robert L Coleman; Bryan T Hennessy; Samuel J Klempner; Henrica M J Werner; Helga B Salvesen; Lewis C Cantley; Gordon B Mills; Andrea P Myers
Journal:  Mol Oncol       Date:  2015-05-16       Impact factor: 6.603

4.  Structural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancer.

Authors:  Iris N Smith; James M Briggs
Journal:  Proteins       Date:  2016-08-13

5.  Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Authors:  Elias Sozopoulos; Helen Litsiou; Gerassimos Voutsinas; Nikolaos Mitsiades; Nikolaos Anagnostakis; Thomais Tseva; Efstratios Patsouris; Sofia Tseleni-Balafouta
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

6.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

7.  The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.

Authors:  K Shoji; K Oda; S Nakagawa; S Hosokawa; G Nagae; Y Uehara; K Sone; Y Miyamoto; H Hiraike; O Hiraike-Wada; T Nei; K Kawana; H Kuramoto; H Aburatani; T Yano; Y Taketani
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.

Authors:  Hua-Chuan Zheng; Yi-Ling Li; Jin-Min Sun; Xue-Fei Yang; Xiao-Han Li; Wei-Guo Jiang; Yin-Chang Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

Review 9.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

10.  PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.

Authors:  Lin Yang; Li-Ge Kuang; Hua-Chuan Zheng; Jin-Yi Li; Dong-Ying Wu; Su-Min Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.